English
This article is from Indian Journal of Palliative Care , volume 19 . Abstract Aims:: In this paper, we have reported a previously undescribed risk factor of deterioration of renal function in zoledronic acid treatment of skeletal metastasis – high serum calcium level. Based on this consideration, a modified method of treatment of hypercalcemia (HCM) with zoledronic acid is suggested in this paper. Material and Methods:: Bone scan findings of 1090 cancer patients were analyzed, of which 26 had intense renal parenchymal uptake as a result of HCM or bone metastases. Subsequently, a total of 56 bone metastases patients with zoledronic acid treatment were divided into three groups: HCM group who were pre-treated to normal serum calcium level (13 patients), HCM group (19 patients), and normal serum calcium group (24 patients). Results:: More patients with intense renal parenchymal uptake were hyperglycemic, statistically significantly (18/26 versus 19/1064, P = 2.1, E-78). No more patients with intense renal parenchymal uptake were associated with bone metastases (14/26 versus 438/1064, P = 0.20). Subsequently, more HCM patients receiving zoledronic acid treatment showed renal injury com
Sign in with your free account to read, download EPUBs or listen.
Ebook · A Modified Method for Reducing Renal Injury in Zoledronic Acid Treatment of Hypercalcemia and Adverse Skeletal Events. · Liu, Jiang, Zheng, Liqun, Zhang, Wenhua, Chang, Keli, Pang, Yan · Internet Archive